New hope for tough leukemia? early trial of AOH1996 begins

NCT ID NCT06763341

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 5 times

Summary

This early-stage trial is testing a new drug called AOH1996 in 12 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The drug works by blocking a protein that helps cancer cells grow and repair themselves. The main goals are to find a safe dose and check for side effects, while also watching for any signs that the drug is helping.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AOH1996 (a PCNA inhibitor drug)
What this could lead to: If it works, this could point toward a new treatment option for patients with AML that has returned or not responded to prior therapies.
What could go wrong: This is a very early Phase 1 trial with only 12 participants, so the main goal is safety, not proof of effectiveness. The drug may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.